Dr Roya Behrouzi

RCLCF Clinical Research Fellow & Specialty Registrar in Medical Oncology @cruk_nbc @TheChristieNHS

[Jen L, PhD Journal Executive Editor @drjkyl]

State of the art in treatment of small cell lung cancer

@TAMedOncol
@SageJournals

https://t.co/smnjsgUJF2

#cancerbiomarkers #chemotherapy #immunotherapy #SCLC #targetedtherapy #oncology #openaccess

[Federico Nichetti @fedenichetti]

5-FU does not synergize with DNA-damaging agents such as oxaliplatin or irinotecan ⁦@CellRepMed⁩ https://t.co/qY63tMf4Nw

[The Christie NHS @TheChristieNHS]

📰 #InTheNews A new drug combination trialled at The Christie stops advanced lung cancer with EGFR mutations from progressing for longer than the drug that's currently in use.

More in the Guardian 👇 https://t.co/z0Jt5WAN1k

[Jon Lim, MRCP PhD @DrJonLim]

Great to rejoin the Manchester Immuno-Oncology Network #MION 🐝 at the first seminar of the 2024-2025 academic year.

Looking forward to many fruitful collaborations 🤝 between scientists & clinicians. @MCRCnews

Excellent talks from @IkShinChin1 @giampazolias @JonathanWorboys!

[Tom Newsom-Davis @tnewsomdavis]

Radiomics for early detection pneumonitis in PACIFIC: @DrJNaidoo

👉 x4 variables, inc clinical data
✅ Identifies symptomatic pneumonitis: PPV 0.46, NPV 0.93

🤔 Can it detect baseline asymptomatic ILD, to ⬇️ risk of future treatment associated pneumonitis?

#ESMO2024 #LCSM

[Pulmonary Cell News @pulmonary_news]

In this new review, Dr. @Roya_Behrouzi at @TheChristieNHS and team discuss how cell-free DNA profiling modalities can be harnessed to expand the clinical applications of liquid biopsy in small cell lung cancer.

https://t.co/7Pqtc78GBm

[Florent Mouliere @FlorentMouliere]

Please to share our work published in @iScience_CP comparing #cfDNA and small #extracellularvesicle DNA sequencing from the plasma of lung cancer patients. #liquidbiopsy
https://t.co/4onyatcQWQ [https://t.co/bm01wkHSr9]

[Trends in Molecular Medicine @TrendsMolecMed]

ONLINE NOW: Cell-free and extrachromosomal DNA profiling of small cell lung cancer https://t.co/c9GTjExym7

[Florent Mouliere @FlorentMouliere]

@Roya_Behrouzi @TrendsMolecMed @cruk_nbc @CRUK_MI @UoM_DCS @FBMH_UoM @MCRCnews @ManchesterBRC @CellPressNews @IASLC @EACRnews @myESMO @BTOGORG @ChristieLibrary @UoMLibrary Well done @Roya_Behrouzi ! #cfDNA #liquidbiopsy #ecDNA #SCLC @cruk_nbc

[Dr Roya Behrouzi @Roya_Behrouzi]

Pleased to share our review published in @TrendsMolecMed on cell-free and extrachromosomal DNA profiling of small cell lung cancer

👉 https://t.co/wcDPvedcbe

Based on my MSc Precision Medicine research project supervised by Dr @FlorentMouliere at @cruk_nbc

@CRUK_MI @UoM_DCS

[Mathew Carter @mathew_carter1]

Mariposa study. Congratulations to the authors @caliraf and colleagues and all those who contributed @philruss3. @myESMO @MCRCnews

[Arndt Vogel @ArndtVogel]

Distinct clinical outcomes & biological features of
specific KRAS mutants in human pancreatic cancer
@Cancer_Cell
https://t.co/eZ0nLO7vWT
👉KRASG12R enriched in early stage w/ reduced nodal disease + distant recurrence
👉improved OS
🧐 Supports KRAS mutational testing in #PDAC
@my@myesmo

[Lewis Au @lewisjwau]

Out now our review on #BispecificAntibodies @trendscancer!👉https://t.co/SnbW24a3X6

We cover preclinical & clinical developments, trials data & challenges ahead

A joy working w the dream team! @mer_herreraMD @GiuliaPretelli @MaassThiago @lillian_siu @ElenaGarralda Jayesh Desai

[Raffaele Califano @caliraf]

The Lung Team at the Christie is currently recruiting in studies for patients with stage 4 ROS1+ NSCLC who have received at least one previous line of treatment. If interested, please email [email protected] @BTOGORG @ros1cancer

[Paolo Tarantino @PTarantinoMD]

HER2: a remarkable story of precision oncology.

Check this wonderful Nature review on targeting HER2 beyond breast.

👉Important to remember: now that we have an agnostic anti-HER2 drug approved (T-DXd), every adv cancer patient should get HER2 testing!

https://t.co/ptTRYd6aEF

[Olivier Elemento @ElementoLab]

Wow! GLP-1 receptor agonists now linked to a substantial reduction in incidence for 10 types of cancers, in patients with Type 2 Diabetes !https://t.co/xUiXl0wUAy

[Yakup Ergün @dr_yakupergun]

Extravasation management of vesicant and irritant agents👇

@OncoAlert

[Raffaele Califano @caliraf]

Mariposa trial - Just published
@mathew_carter1
@philruss3 @irrandulfe
@TheChristieNHS
@UoM_DCS @SharonWoolley1
@BTOGORG

https://t.co/6S7Bc0seMW

[Simona Cristea @simocristea]

new @ScienceMagazine framework to improve cancer early detection:

two injectable priming agents (nanoparticles & engineered antibodies) temporarily slow down the clearance of circulating tumor DNA from the body, allowing for higher detection sensitivity

https://t.co/YDRYRk7L5a

[CRUK National Biomarker Centre @cruk_nbc]

It’s our launch day!! 🥳